US20020198198A1 - Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors - Google Patents

Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors Download PDF

Info

Publication number
US20020198198A1
US20020198198A1 US10/101,996 US10199602A US2002198198A1 US 20020198198 A1 US20020198198 A1 US 20020198198A1 US 10199602 A US10199602 A US 10199602A US 2002198198 A1 US2002198198 A1 US 2002198198A1
Authority
US
United States
Prior art keywords
dihydro
cyclohexane
quinazolin
lower alkyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/101,996
Other languages
English (en)
Inventor
Patrick Bernardelli
Pierre Ducrot
Edwige Lorthiois
Fabrice Vergne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8164349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20020198198(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of US20020198198A1 publication Critical patent/US20020198198A1/en
Assigned to WARNER-LAMBERT COMPANY LLC reassignment WARNER-LAMBERT COMPANY LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BERNARDELLI, PATRICK, DUCROT, PIERRE, LORTHIOIS, EDWIGE, VERGNE, FABRICE
Priority to US10/852,404 priority Critical patent/US7214676B2/en
Priority to US11/551,687 priority patent/US20070049558A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the invention relates to spirotricyclic derivatives, the process for their preparation, and their use as phosphodiesterase 7 (PDE7) inhibitors.
  • Phosphodiesterases play an important role in various biological processes by hydrolysing the key second messengers adenosine and guanosine 3′,5′-cyclic monophosphates (cAMP and cGMP respectively) into their corresponding 5′-monophosphate nucleotides. Therefore, inhibition of PDE activity produces an increase of cAMP and cGMP intracellular levels that activate specific protein phosphorylation pathways involved in a variety of functional responses.
  • At least eleven isoenzymes of mammalian cyclic nucleotide phosphodiesterases numbered PDE 1 through PDE 11, have been identified on the basis of primary structure, substrate specificity or sensitivity to cofactors or inhibitory drugs.
  • PDE7 is a cAMP-specific PDE.
  • PDE7 activity or protein has been detected in T-cell lines, B-cell lines, airway epithelial (AE) cell lines and several foetal tissues.
  • AE airway epithelial
  • AE cells actively participate in inflammatory airway diseases by liberating mediators such as arachidonate metabolites and cytokines.
  • mediators such as arachidonate metabolites and cytokines.
  • Selective inhibition of PDE7 may be a useful anti-inflammatory approach for treating AE cells related diseases.
  • WO 88/01508 discloses compounds of formula
  • R is hydrogen, alkyl, alkoxyalkyl, hydroxyalkyl, halo, cyano, carbamoyl, alkyl carbamoyl, formyl, alkylamino or amino;
  • X is —(CR4R5)a-NR6-(CR4R5)b-;
  • R1, R2, R3, and R5 are hydrogen or alkyl
  • R4 and R5 groups on vicinal carbon atoms may together form a carbon-carbon double bond; and geminal R4 and R5 groups may together form a spiro substitutent, —(CH2)d-, where d is 2 to 5; or a pharmaceutically acceptable salt thereof. These compounds are described as cardiotonics.
  • WO 00/66560 discloses compounds of formula
  • the invention provides the use of spirotricyclic derivatives, which are PDE inhibitors and more particularly PDE7 inhibitors, having the following formula (I), (II) or (III):
  • X 1 , X 2 , X 3 and X 4 are the same or different and are selected from:
  • N provided that not more than two of the groups X 1 , X 2 , X 3 and X 4 simultaneously represent a nitrogen atom, or,
  • R 1 is selected from:
  • X 5 is selected from:
  • R 5 is selected from aryl, heteroaryl, cycloalkyl optionally interrupted
  • heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, or a bicyclic group, these groups being unsubstituted or substituted with one or several groups selected from Q3, heteroaryl or lower alkyl optionally substituted with Q3;
  • OR 2 OC( ⁇ O)R 2 , C( ⁇ O)OR 2 , SR 2 , S( ⁇ O)R 2 , C( ⁇ O)—NH—SO 2 —CH 3 , NR 3 R 4 , Q-R 2 , Q-NR 3 R 4 , NR 2 -Q-NR 3 R 4 or NR 3 -Q-R 2 in which Q is selected from C( ⁇ NR), C( ⁇ O), C( ⁇ S) or SO 2 , R is selected from hydrogen, CN, SO 2 NH 2 or lower alkyl and R 2 , R 3 and R 4 are the same or different and are selected from:
  • lower alkyl optionally interrupted with C( ⁇ O), Q4-aryl, Q4-heteroaryl, Q4-cycloalkyl optionally interrupted with C( ⁇ O) or with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, or Q4-cycloalkenyl optionally interrupted with C( ⁇ O) or with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, in which
  • Q4 is selected from (CH 2 ) n , lower alkyl interrupted with one heteroatom selected from O, S or N, lower alkenyl or lower alkynyl, these groups being optionally substituted with lower alkyl, OR′ or NR′R′′ in which R′ and R′′ are the same or different and are selected from hydrogen or lower alkyl;
  • n is an integer selected from 0, 1, 2, 3 or 4;
  • these groups being unsubstituted or substituted with one or several groups selected from lower alkyl, halogen, CN, CH 3 , SO 3 H, SO 2 CH 3 , C( ⁇ O)—NH—SO 2 —CH 3 , CF 3 , OR 6 , COOR 6 , C( ⁇ O)R 6 , NR 6 R 7 , NR 6 C( ⁇ O)R 7 , C( ⁇ O)NR 6 R 7 or SO 2 NR 6 R 7 , in which R 6 and R 7 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with one or two groups selected from OR, COOR or NRR 8 in which R and R 8 are hydrogen or lower alkyl, and,
  • R 6 and R 7 , and/or, R 3 and R 4 , together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S, S( ⁇ O), SO 2 or N, and which may be substituted with,
  • a lower alkyl optionally substituted with OR′, NR′R′′, C( ⁇ O)NR′R′′ or COOR′ in which R′ and R′′ are the same or different and are selected from,
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and,
  • R′ and R′′ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N; or,
  • X 1 and X 2 both represent C—R 1
  • the 2 substituents R 1 may form together with the carbon atoms to which they are attached, a 5-membered heterocyclic ring comprising a nitrogen atom and optionally a second heteroatom selected from O, S or N;
  • X is O, S or NR 9 , in which R 9 is selected from,
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with cycloalkyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, cycloalkenyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, aryl, heteroaryl, OR 10 , COOR 10 or NR 10 R 11 in which R 10 and R 11 are the same or different and are selected from hydrogen or lower alkyl;
  • Y is selected from O, S or N—R 12 , in which R 12 is selected from:
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with cycloalkyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, cycloalkenyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, aryl, heteroaryl, R 10 , COOR 10 or NR 10 R 11 in which R 10 and R 11 are the same or different and are selected from hydrogen or lower alkyl;
  • Z is chosen from CH—NO 2 , O, S or NR 13 in which R 13 is selected from:
  • R 14 and R 15 being independently selected from hydrogen or lower alkyl, or, R 14 and R 15 , together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms chosen from O, S or N, and which may be substituted with a lower alkyl, or,
  • R 12 and R 13 may form together a —CH ⁇ N— group or a —C ⁇ C— group,
  • R 9 and R 13 may form together a —CH ⁇ N— group or a —C ⁇ C— group;
  • Z 1 is chosen from H, CH 3 or NR 16 R 17 in which R 16 and R 17 are the same or different and are selected from:
  • lower alkyl unsubstituted or substituted with one or several groups selected from OR 14 , COOR 14 or NR 14 R 15 ,
  • R 14 and R 15 being chosen from hydrogen or lower alkyl, and,
  • R 14 and R 15 , and/or, R 16 and R 17 , together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms chosen from O, S or N, and which may be substituted with a lower alkyl;
  • A is a cycle chosen from:
  • a 1 , A 2 , A 3 , A 4 , A 5 and A 6 are the same or different and are selected from O, S, C, C( ⁇ O), SO, SO 2 or N—R 18 in which R 18 is selected from:
  • aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N
  • cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N
  • [0070] * represents the carbon atom which is shared between the cycle A and the backbone cycle containing X and/or Y;
  • each carbon atom of the cycle A is unsubstituted or substituted with 1 or 2 groups, identical or different, selected from lower alkyl optionally substituted with OR 21 , NR 21 R 22 , COOR 21 or CONR 21 R 22 , lower haloalkyl, CN, F, ⁇ O, SO 2 NR 19 R 20 , OR 19 , SR 19 , C( ⁇ O)OR 19 , C( ⁇ O)NR 19 R 20 or NR 19 R 20 in which R 19 and R 20 are identical or different and are selected from hydrogen or lower alkyl optionally substituted with OR 21 , NR 21 R 22 , COOR 21 or CONR 21 R 22 in which R 21 and R 22 are identical or different and are selected from hydrogen or lower alkyl, and,
  • R 19 and R 20 , and/or, R 21 and R 22 , together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • 2 atoms of the cycle A which are not adjacent, may be linked by a 2, 3 or 4 carbon atom chain which may be interrupted with 1 heteroatom chosen from O, S or N;
  • the invention also relates to compounds, which are PDE7 inhibitors, having the following formula (I), (II) or (III)
  • X 1 , X 2 , X 3 and X 4 are the same or different and are selected from:
  • N provided that not more than two of the groups X 1 , X 2 , X 3 and X 4 simultaneously represent a nitrogen atom, or,
  • R 1 is selected from:
  • X 5 is selected from:
  • R 5 is selected from aryl, heteroaryl, cycloalkyl optionally interrupted with C( ⁇ O) or with 1, 2, or 3 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, cycloalkenyl optionally interrupted with C( ⁇ O) or with 1, 2, or 3 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, or a bicyclic group, these groups being unsubstituted or substituted with one or several groups selected from Q3, heteroaryl or lower alkyl optionally substituted with Q3;
  • lower alkyl optionally interrupted with C( ⁇ O), Q4-aryl, Q4-heteroaryl, Q4-cycloalkyl optionally interrupted with C( ⁇ O) or with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, or Q4-cycloalkenyl optionally interrupted with C( ⁇ O) or with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, in which
  • Q4 is selected from (CH 2 ) n , lower alkyl interrupted with one heteroatom selected from O, S or N, lower alkenyl or lower alkynyl, these groups being optionally substituted with lower alkyl, OR′ or NR′R′′ in which R′ and R′′ are the same or different and are selected from hydrogen or lower lower alkyl;
  • n is an integer selected from 0, 1, 2, 3 or 4;
  • these groups being unsubstituted or substituted with one or several groups selected from lower alkyl, halogen, CN, CH 3 , SO 3 H, SO 2 CH 3 , C( ⁇ O)—NH—SO 2 —CH 3 , CF 3 , OR 6 , COOR 6 , C( ⁇ O)R 6 , NR 6 R 7 , NR 6 C( ⁇ O)R 7 , C( ⁇ O)NR 6 R 7 or SO 2 NR 6 R 7 , in which R 6 and R 7 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with one or two groups selected from OR, COOR or NRR 8 in which R and R 8 are hydrogen or lower alkyl, and,
  • R 6 and R 7 , and/or, R 3 and R 4 , together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S, S( ⁇ O), SO 2 , or N, and which may be substituted with,
  • a lower alkyl optionally substituted with OR′, NR′R′′, C( ⁇ O)NR′R′′ or COOR′ in which R′ and R′′ are the same or different and are selected from,
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and,
  • R′ and R′′ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N; or,
  • R 1 when X 1 and X 2 both represent C—R 1 , the 2 substituents R 1 may form together with the carbon atoms to which they are attached, a 5-membered heterocyclic ring comprising a nitrogen atom and optionally a second heteroatom selected from O, S or N;
  • X is O or NR 9 , in which R 9 is selected from,
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with cycloalkyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, cycloalkenyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, aryl, heteroaryl, OR 10 , COOR 10 or NR 10 R 11 in which R 10 and R 11 are the same or different and are selected from hydrogen or lower alkyl;
  • Y is selected from O, S or N—R 12 , in which R 12 is selected from:
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with, cycloalkyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, cycloalkenyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, aryl, heteroaryl, OR 10 , COOR 10 or NR 10 R 11 in which R 10 and R 11 are the same or different and are selected from hydrogen or lower alkyl;
  • Z is chosen from CH—NO 2 , O, S or NR 13 in which R 13 is selected from:
  • lower alkyl unsubstituted or substituted with one or several groups which are the same or different and which are selected OR 14 , COOR 10 or NR 14 R 15 ;
  • R 14 and R 15 being independently selected from hydrogen or lower alkyl, or, R 14 and R 15 , together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms chosen from O, S or N, and which may be substituted with a lower alkyl, or,
  • Y is N—R 12 and Z is N—R 13 , may form together a —CH ⁇ N— group or a —C ⁇ C— group,
  • R 9 and R 13 may form together a —CH ⁇ N— group or a —C ⁇ C— group;
  • Z 1 is chosen from H, CH 3 or NR 16 R 17 in which R 16 and R 17 are the same or different and are selected from:
  • R 14 and R 15 being chosen from hydrogen or lower alkyl, and,
  • R 14 and R 15 , and/or, R 16 and R 17 , together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms chosen from O, S or N, and which may be substituted with a lower alkyl;
  • A is a cycle chosen from:
  • a 1 , A 2 , A 4 , A 5 and A 6 are the same or different and are selected from O, S, C, C( ⁇ O), SO, SO 2 or N—R 18 in which R 18 is selected from:
  • aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N
  • cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N
  • lower alkyl unsubstituted or substituted with aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, CN, NR 19 R 20 , C( ⁇ O)NR 19 R 20 , OR 19 , C( ⁇ O)R 19 or C( ⁇ O)OR 19 in which R 19 and R 20 are identical or different and are selected from hydrogen or lower alkyl;
  • a 3 is selected from O, S, C, C( ⁇ O), SO or SO 2 , or N—R 18 when A 1 and/or A 2 are C( ⁇ O) or when Y is O or S, wherein R 18 is as defined above;
  • each carbon atom of the cycle A is unsubstituted or substituted. with 1 or 2 groups, identical or different, selected from lower alkyl optionally substituted with OR 21 , NR 21 R 22 , COOR 21 or CONR 21 R 22 , lower haloalkyl, CN, F, ⁇ O, SO 2 NR 19 R 20 , OR 19 , SR 19 , C( ⁇ O)OR 19 , C( ⁇ O)NR 19 R 20 or NR 19 R 20 in which R 19 and R 20 are identical or different and are selected from hydrogen or lower alkyl optionally substituted with OR 21 , NR 21 R 22 , COOR 21 or CONR 21 R 22 in which R 21 and R 22 are identical or different and are selected from hydrogen or lower alkyl, and,
  • R 19 and R 20 , and/or, R 21 and R 22 , together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • 2 atoms of the cycle A which are not adjacent, may be linked by a 2, 3 or 4 carbon atom chain which may be interrupted with 1 heteroatom chosen from O, S or N;
  • the cycle A does not contain more than 2 carbon atoms in an sp 2 hybridization state
  • These compounds are selective PDE7 inhibitors. They can be used in the treatment of various diseases, such as T-cell-related diseases, autoimmune diseases, osteoarthritis, rheumatoid arthritis, multiple sclerosis, osteoporosis, chronic obstructive pulmonary disease (COPD), asthma, cancer, acquired immune deficiency syndrome (AIDS), allergy or inflammatory bowel disease (IBD).
  • diseases such as T-cell-related diseases, autoimmune diseases, osteoarthritis, rheumatoid arthritis, multiple sclerosis, osteoporosis, chronic obstructive pulmonary disease (COPD), asthma, cancer, acquired immune deficiency syndrome (AIDS), allergy or inflammatory bowel disease (IBD).
  • the invention also relates to a process for preparing the above compounds.
  • the invention further concerns the use of a compound of formula (I), (II) or (III) for the preparation of a medicament for the prevention or the treatment of disorders for which therapy by a PDE7 inhibitor is relevant.
  • the invention also provides a method for the treatment of a disorder for which therapy by a PDE7 inhibitor is relevant, comprising administering to a mammal in need thereof an effective amount of compound of formula (I), (II) or (III).
  • the invention also provides a method for the treatment of T-cell-related diseases, autoimmune diseases, osteoarthritis, rheumatoid arthritis, multiple sclerosis, osteoporosis, chronic obstructive pulmonary disease (COPD), asthma, cancer, acquired immune deficiency syndrome (AIDS), allergy or inflammatory bowel disease (IBD), comprising administering to a mammal in need thereof an effective amount of compound of formula (I), (II) or (III).
  • the invention also concerns a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), (II) or (III) together with a pharmaceutically acceptable carrier, excipient, diluent or delivery system.
  • the present invention provides the use of compounds, which are PDE7 inhibitors, having formula (I), (II) or (III),
  • X 1 , X 2 , X 3 and X 4 are the same or different and are selected from:
  • N provided that not more than two of the groups X 1 , X 2 , X 3 and X 4 simultaneously represent a nitrogen atom, or,
  • R 1 is selected from:
  • X 5 is selected from:
  • lower alkyl, lower alkenylene or lower alkynylene optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, ,the carbon atoms of these groups being unsubstituted or substituted with one or several groups, identical or different, selected from SR 6 , OR 6 , NR 6 R 7 , ⁇ O, ⁇ S or ⁇ N—R 6 in which R 6 and R 7 are the same or different and are selected from hydrogen or lower alkyl, and,
  • R 5 is selected from aryl, heteroaryl, cycloalkyl optionally interrupted with C( ⁇ O) or with 1, 2, or 3 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, cycloalkenyl optionally interrupted with C( ⁇ O) or with 1, 2, or 3 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, or a bicyclic group, these groups being unsubstituted or substituted with one or several groups selected from Q3, heteroaryl or lower alkyl optionally substituted with Q3;
  • OR 2 OC( ⁇ O)R 2 , C( ⁇ O)OR 2 , SR 2 , S( ⁇ O)R 2 , NR 3 R 4 , Q-R 2 , Q-NR 3 R 4 , NR 2 -Q-NR 3 R 4 or NR 3 -Q-R 2 in which Q is selected from C( ⁇ NR), C( ⁇ O), C( ⁇ S) or SO 2 , R is selected from hydrogen or lower alkyl and R 2 , R 3 and R 4 are the same or different and are selected from:
  • lower alkyl optionally interrupted with C( ⁇ O), (CH 2 ) n -aryl, (CH 2 ) n -heteroaryl, (CH 2 ) n -cycloalkyl optionally interrupted with C( ⁇ O) or with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N or (CH 2 ) n -cycloalkenyl optionally interrupted with C( ⁇ O) or with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, in which n is an integer selected from 0, 1, 2, 3 or 4;
  • these groups being unsubstituted or substituted with one or several groups selected from lower alkyl, halogen, CN, SO 3 H, CH 3 , SO 2 CH 3 , CF 3 , C( ⁇ O)—NH—SO 2 —CH 3 , OR 6 , COOR 6 , NR 6 R 7 , C( ⁇ O)NR 6 R 7 or SO 2 NR 6 R 7 , in which R 6 and R 7 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with one or two groups selected from OR, COOR or NRR 8 in which R and R 8 are hydrogen or lower alkyl, and,
  • R 6 and R 7 , and/or, R 3 and R 4 , together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S, S( ⁇ O), SO 2 or N, and which may be substituted with,
  • a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or,
  • a lower alkyl optionally substituted with OR′, NR′R′′, C( ⁇ O)NR′R′′ or COOR′ in which R′ and R′′ are the same or different and are selected from,
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and,
  • R′ and R′′ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N;
  • X is O, S or NR 9 , in which R 9 is selected from,
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with cycloalkyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, cycloalkenyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, aryl, heteroaryl, OR 10 or NR 10 R 11 in which R 10 and R 11 are the same or different and are selected from hydrogen or lower alkyl;
  • Y is selected from O, S or N—R 12 , in which R 12 is selected from:
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with, cycloalkyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, cycloalkenyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, aryl, heteroaryl, OR 10 or NR 10 R 11 in which R 10 and R 11 are the same or different and are selected from hydrogen or lower alkyl; d) Z is chosen from CH—NO 2 , O, S or NR 13 in which R 13 is selected from:
  • R 14 and R 15 being independently selected from hydrogen or lower alkyl, or, R 14 and R 15 , together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms chosen from O, S or N, and which may be substituted with a lower alkyl;
  • Z 1 is chosen from H, CH 3 or NR 16 R 17 in which R 16 and R 17 are the same or different and are selected from:
  • R 14 and R 15 being chosen from hydrogen or lower alkyl, and,
  • R 14 and R 15 , and/or, R 16 and R 17 , together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms chosen from O, S or N, and which may be substituted with a lower alkyl;
  • A is a cycle chosen from:
  • a 1 , A 2 , A 3 , A 4 , A 5 and A 6 are the same or different and are selected from O, S, C, C( ⁇ O), SO, SO 2 or N—R 18 in which R 18 is selected from:
  • aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N
  • cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N
  • [0189] represents the carbon atom which is shared between the cycle A and the backbone cycle containing X and/or Y;
  • each carbon atom of the cycle A is unsubstituted or substituted with 1 or 2 groups, identical or different, selected from lower alkyl optionally substituted with OR 21 , NR 21 R 22 , COOR 21 or R 21 or CONR 21 R 22 , lower haloalkyl, CN, F, ⁇ O, SO 2 NR 19 R 20 , OR 19 , SR 19 , C( ⁇ O)OR 19 , C( ⁇ O)NR 19 R 20 or NR 19 R 20 in which R 19 and R 20 are identical or different and are selected from hydrogen or lower alkyl optionally substituted with OR 21 , NR 21 R 22 , COOR 21 or CONR 21 R 22 in which R 21 and R 22 are identical or different and are selected from hydrogen or lower alkyl, and,
  • R 19 and R 20 , and/or, R 21 and R 22 , together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • 2 atoms of the cycle A which are not adjacent, may be linked by a 2, 3 or 4 carbon atom chain which may be interrupted with 1 heteroatom chosen from O, S or N;
  • X 1 , X 2 and X 3 are the same or different and are C—R 1 , in which R 1 is selected from:
  • R 6 and R 7 together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from halogen, CN, OR 2 , COOR 2 , NR 3 R 4 , SO 2 NR 3 R 4 or C( ⁇ O)NR 3 R 4 in which R 2 , R 3 and R 4 are the same or different and are selected from hydrogen or lower alkyl, and,
  • R 3 and R 4 together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • X 5 is selected from a lower alkylene or a single bond, and,
  • R 5 is selected from phenyl, pyridyl or indolyl, these groups being unsubstituted or substituted with one or several groups selected from Q3, heteroaryl or lower alkyl optionally substituted with Q3 in which Q3 is selected from:
  • R 6 and R 7 , and/or, R 3 and R 4 , together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N, and which may be substituted with
  • a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or,
  • a lower alkyl optionally substituted with OR′, NR′R′′, C( ⁇ O)NR′R′′ or COOR′ in which R′ and R′′ are the same or different and are selected from
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and,
  • R′ and R′′ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N;
  • X 4 is C—R 1 in which R 1 is selected from hydrogen, halogen, CN, NO 2 , SO 2 CH 3 , SO 3 H, CH 3 , CF 3 , OR 2 , SR 2 , NR 2 R 3 , COOR 2 , CONR 2 R 3 , SO 2 NR 2 R 3 in which R 2 and R 3 are the same or different and are selected from hydrogen or lower alkyl;
  • Z 1 is chosen from NR 16 R 17 in which R 16 and R 17 are the same or different and are selected from:
  • R 14 and R 15 being chosen from hydrogen or lower alkyl, and,
  • R 14 and R 15 , and/or, R 16 and R 17 , together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms selected from O, S or N, and which may be substituted with a lower alkyl;
  • A is a cycle chosen from:
  • a 1 , A 2 , A 3 , A 4 and A 5 are the same or different and are selected from:
  • a carbon atom unsubstituted or substituted with 1 or 2 groups, identical or different selected from lower alkyl, OH or F, or,
  • X 1 , X 2 and X 3 are the same or different and are C—R 1 , in which R 1 is selected from:
  • R 6 and R 7 together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from halogen, CN, SO 3 H, OR 2 , COOR 2 , NR 3 R 4 , SO 2 NR 3 R 4 or C( ⁇ O)NR 3 R 4 in which R 2 , R 3 and R 4 are the same or different and are selected from hydrogen or lower alkyl, and,
  • R 3 and R 4 together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • X 5 is selected from a lower alkylene or a single bond, and,
  • R 5 is selected from phenyl, pyridyl or indolyl,
  • R 6 and R 7 , and/or, R 3 and R 4 , together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N, and which may be substituted with,
  • a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or,
  • a lower alkyl optionally substituted with OR′, NR′R′′, C( ⁇ O)NR′R′′ or COOR′ in which R′ and R′′ are the same or different and are selected from,
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and,
  • R′ and R′′ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N;
  • X 4 is C—R 1 in which R 1 is selected from hydrogen, halogen, CN, NO 2 , SO 2 CH 3 , SO 3 H, CH 3 , CF 3 , OR 2 , SR 2 , NR 2 R 3 , COOR 2 , CONR 2 R 3 , SO 2 NR 2 R 3 in which R 2 and R 3 are the same or different and are selected from hydrogen or lower alkyl;
  • Z is chosen from O, S or NR 13 in which R 13 is hydrogen or CN;
  • A is a cycle chosen from:
  • a 1 , A 2 , A 3 , A 4 and A 5 are the same or different and are selected from:
  • a preferred group of compounds of formula (II) or (III) are those in which,
  • X 1 , X 2 and X 3 are the same or different and are C—R 1 , in which R 1 is selected from:
  • R 6 and R 7 together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from halogen, CN, OR 2 , COOR 2 , NR 3 R 4 , SO 2 NR 3 R 4 or C( ⁇ O)NR 3 R 4 in which R 2 , R 3 and R 4 are the same or different and are selected from hydrogen or lower alkyl, and,
  • R 3 and R 4 together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • X 5 is selected from a lower alkylene or a single bond, and,
  • R 5 is selected from phenyl, pyridyl or indolyl,
  • R 6 and R 7 , and/or, R 3 and R 4 , together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N, and which may be substituted with
  • a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or,
  • a lower alkyl optionally substituted with OR′, NR′R′′, C( ⁇ O)NR′R′′ or COOR′ in which R′ and R′′ are the same or different and are selected from
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and,
  • R′ and R′′ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N;
  • X 4 is C—R 1 in which R 1 is selected from hydrogen, halogen, CN, NO 2 , SO 2 CH 3 , SO 3 H, CH 3 , CF 3 , OR 2 , SR 2 , NR 2 R 3 , COOR 2 , CONR 2 R 3 or SO 2 NR 2 R 3 in which R 2 and R 3 are the same or different and are selected from hydrogen or lower alkyl;
  • Z 1 is chosen from NR 16 R 17 in which R 16 and R 17 are the same or different and are selected from:
  • R 14 and R 15 being chosen from hydrogen or lower alkyl, and,
  • R 14 and R 15 , and/or, R 16 and R 17 , together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms selected from O, S or N, and which may be substituted with a lower alkyl;
  • A is a cycle chosen from:
  • a 1 , A 2 , A 3 , A 4 and A 5 are the same or different and are selected from:
  • a preferred group of compounds of formula (II) or (III) are the one in which X 1 , X 2 , X 3 , X 4 , X, Y, Z 1 and A are as disclosed hereabove wherein when X 2 is C—R 1 and R 1 is X 5 —R 5 , then X 5 is not a single bond;
  • X 1 , X 2 , X 3 and X 4 are the same or different and are selected from:
  • N provided that not more than two of the groups X 1 , X 2 , X 3 and X 4 simultaneously represent a nitrogen atom, or,
  • R 1 is selected from:
  • X 5 is selected from:
  • R 5 is selected from aryl, heteroaryl, cycloalkyl optionally interrupted with C( ⁇ O) or with 1, 2, or 3 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, cycloalkenyl optionally interrupted with C( ⁇ O) or with 1, 2, or 3 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, or a bicyclic group, these groups being unsubstituted or substituted with one or several groups selected from Q3, heteroaryl or lower alkyl optionally substituted with Q3;
  • OR 2 OC( ⁇ O)R 2 , C( ⁇ O)OR 2 , SR 2 , S( ⁇ O)R 2 , NR 3 R 4 , Q-R 2 , Q-NR 3 R 4 , NR 2 -Q-NR 3 R 4 or NR 3 -Q-R 2 in which Q is selected from C( ⁇ NR), C( ⁇ O), C( ⁇ S) or SO 2 , R is selected from hydrogen or lower alkyl and R 2 , R 3 and R 4 are the same or different and are selected from:
  • lower alkyl optionally interrupted with C( ⁇ O), (CH 2 ) n -aryl, (CH 2 ) n -heteroaryl, (CH 2 ) n -cycloalkyl optionally interrupted with C( ⁇ O) or with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N or (CH 2 ) n -cycloalkenyl optionally interrupted with C( ⁇ O) or with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, in which n is an integer selected from 0, 1, 2 or 3;
  • these groups being unsubstituted or substituted with one or several groups selected from lower alkyl, halogen, CN, SO 3 H, CH 3 , SO 2 CH 3 , CF 3 , C( ⁇ O)—NH—SO 2 —CH 3 , OR 6 , COOR 6 , NR 6 R 7 , C( ⁇ O)NR 6 R 7 or SO 2 NR 6 R 7 , in which R 6 and R 7 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with one or two groups selected from OR, COOR or NRR 8 in which R and R 8 are hydrogen or lower alkyl, and,
  • R 6 and R 7 , and/or, R 3 and R 4 , together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S, S( ⁇ O), SO 2 or N, and which may be substituted with
  • a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or,
  • a lower alkyl optionally substituted with OR′, NR′R′′, C( ⁇ O)NR′R′′ or COOR′ in which R′ and R′′ are the same or different and are selected from
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and,
  • R′ and R′′ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N;
  • X is NR 9 , in which R 9 is selected from,
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with cycloalkyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, cycloalkenyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, aryl, heteroaryl, OR 10 or NR 10 R 11 in which R 10 and R 11 are the same or different and are selected from hydrogen or lower alkyl;
  • Y is selected from O, S or N—R 12 , in which R 12 is selected from:
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with, cycloalkyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, cycloalkenyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, aryl, heteroaryl, OR 10 or NR 10 R 11 in which R 10 and R 11 are the same or different and are selected from hydrogen or lower alkyl;
  • Z is chosen from CH—NO 2 , O, S or NR 13 in which R 13 is selected from:
  • R 14 and R 15 being independently selected from hydrogen or lower alkyl, or, R 14 and R 15 , together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms chosen from O, S or N, and which may be substituted with a lower alkyl;
  • A is a cycle chosen from:
  • a 1 , A 2 , A 4 , A 5 and A 6 are the same or different and are selected from O, S, C, C( ⁇ O), SO, SO 2 or N—R 18 in which R 18 is selected from:
  • aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N
  • cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N
  • a 3 is selected from O, S, C, C( ⁇ O), SO or SO 2, or N—R 18 when A 1 and/or A 2 are C( ⁇ O) or when Y is O or S, wherein R 18 is as defined above;
  • each carbon atom of the cycle A is unsubstituted or substituted with 1 or 2 groups, identical or different, selected from lower alkyl optionally substituted with OR 21 , NR 21 R 22 , COOR 21 or CONR 21 R 22 , lower haloalkyl, CN, F, ⁇ O, SO 2 NR 19 R 20 , OR 19 , SR 19 , C( ⁇ O)OR 19 , C( ⁇ O)NR 19 R 20 or NR 19 R 20 in which R 19 and R 20 are identical or different and are selected from hydrogen or lower alkyl optionally substituted with OR 21 , NR 21 R 22 , COOR 21 or CONR 21 R 22 in which R 21 and R 22 are identical or different and are selected from hydrogen or lower alkyl, and,
  • R 19 and R 20 , and/or, R 21 and R 22, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • 2 atoms of the cycle A which are not adjacent, may be linked by a 2, 3 or 4 carbon atom chain which may be interrupted with 1 heteroatom chosen from O, S or N;
  • the cycle A does not contain more than 2 carbon atoms in an Sp2 hybridization state.
  • a preferred group of compounds of formula (I) is a group in which X 1 , X 2 , X 3 , X 4 , X, Y, Z and A are as disclosed hereabove wherein when X 2 is C—R 1 and R 1 is X 5 —R 5 , then X 5 is not a single bond;
  • Preferred compounds of formula (I) are those in which,
  • X 1 , X 2 , X 3 and X 4 are the same or different and are selected from:
  • N provided that not more than two of the groups X 1 , X 2 , X 3 and X 4 simultaneously represent a nitrogen atom, or,
  • R 1 is selected from:
  • X 5 is selected from:
  • R 5 is selected from aryl, heteroaryl, cycloalkyl optionally interrupted with C( ⁇ O) or with 1, 2, or 3 heteroatoms chosen from O, S or N, cycloalkenyl optionally interrupted with C( ⁇ O) or with 1, 2, or 3 heteroatoms chosen from O, S or N, or a bicyclic group,
  • these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from Q3, heteroaryl or lower alkyl optionally substituted with Q3;
  • Q1, Q2, Q3 are the same or different and are selected from:
  • OR 2 OC( ⁇ O)R 2 , C( ⁇ O)OR 2 , SR 2 , S( ⁇ O)R 2 , NR 3 R 4 , Q-R 2 , Q-NR 3 R 4 , NR 2 -Q-NR 3 R 4 or NR 3 -Q-R 2 in which Q is selected from C( ⁇ NR), C( ⁇ O), C( ⁇ S) or SO 2 , R is selected from hydrogen or lower alkyl and R 2 , R 3 and R 4 are the same or different and are selected from:
  • lower alkyl optionally interrupted with C( ⁇ O), (CH 2 ) n -aryl, (CH 2 ) n -heteroaryl, (CH 2 ) n -cycloalkyl optionally interrupted with C( ⁇ O) or with 1 or 2 heteroatoms chosen from O, S or N or (CH 2 ) n -cycloalkenyl optionally interrupted with C( ⁇ O) or with 1 or 2 heteroatoms chosen from O, S or N, in which n is an integer selected from 0, 1, 2 or 3;
  • these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from halogen, CN, SO 3 H, CH 3 , SO 2 CH 3 , CF 3 , OR 6 , COOR 6 , NR 6 R 7 , C( ⁇ O)NR 6 R 7 or SO 2 NR 6 R 7 , in which R 6 and R 7 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with one or two groups selected from OR, COOR or NRR 8 in which R and R 8 are hydrogen or lower alkyl, and,
  • R 6 and R 7 , and/or, R 3 and R 4 , together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S, S( ⁇ O), SO 2 or N, and which may be substituted with
  • a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or,
  • a lower alkyl optionally substituted with OR′, NR′R′′, C( ⁇ O)NR′R′′ or COOR′ in which R′ and R′′ are the same or different and are selected from
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and,
  • R′ and R′′ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N;
  • Z is chosen from O, S or NR 13 in which R 13 is hydrogen or CN;
  • A is a cycle chosen from:
  • a 1 , A 2 , A 4 and A 5 are the same or different and are selected from O, S, C, C( ⁇ O), SO, SO 2 or N—R 18 in which R 18 is selected from:
  • aryl, heteroaryl, cycloalkyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N
  • cycloalkenyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N
  • a 3 is selected from O, S, C, C( ⁇ O), SO or SO 2 , or N—R 18 when A 1 and/or A 2 are C( ⁇ O) or when Y is 0 or S, wherein R 18 is as defined above;
  • [0381] represents the carbon atom which is shared between the cycle A and the backbone cycle containing X and/or Y;
  • each carbon atom of the cycle A is unsubstituted or substituted with 1 or 2 groups, identical or different, selected from lower alkyl optionally substituted with OR 21 , NR 21 R 22 , COOR 21 or CONR 21 R 22 , lower haloalkyl, CN, F, ⁇ O, SO 2 NR 19 R 20 , OR 19 , SR 19 , C( ⁇ O)OR 19 or C( ⁇ O)NR 19 R 20 or NR 19 R 20 in which R 19 and R 20 are identical or different and are selected from hydrogen or lower alkyl optionally substituted with OR 21 , NR 21 R 22 , COOR 21 or CONR 21 R 22 in which R 21 and R 22 are identical or different and are selected from hydrogen or lower alkyl, and,
  • R 19 and R 20 , and/or, R 21 and R 22 , together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • 2 atoms of the cycle A which are not adjacent, may be linked by a 2, 3 or 4 carbon atom chain which may be interrupted with 1 heteroatom chosen from O, S or N;
  • the cycle A does not contain more than 2 carbon atoms in an Sp 2 hybridization state.
  • a preferred group of compounds of formula (I) is a group in which X 1 , X 2 , X 3 , X 4 , X, Y, Z and A are as disclosed hereabove wherein when X 2 is C—R 1 and R 1 is X 5 —R 5 , then X 5 is not a single bond;
  • X 1 , X 2 and X 3 are the same or different and are C—R 1 , in which R 1 is selected from:
  • R 6 and R 7 together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from halogen, CN, SO 3 H, OR 2 , COOR 2 , NR 3 R 4 , SO 2 NR 3 R 4 or C( ⁇ O)NR 3 R 4 in which R 2 , R 3 and R 4 are the same or different and are selected from hydrogen or lower alkyl, and,
  • R 3 and R 4 together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • X 5 is selected from a lower alkylene or a single bond, and,
  • R 5 is selected from phenyl, pyridyl or indolyl, these groups being unsubstituted or substituted with 1, 2 or 3 groups 30 selected from Q3, heteroaryl or lower alkyl optionally substituted with Q3 in which Q3 is selected from:
  • halogen CN, SO 3 H, NO 2 , CF 3 , OR 2 , OC( ⁇ O)R 2 , C( ⁇ O)R 2 , C( ⁇ O)OR 2 , NH—C( ⁇ O)R 2 , NR 3 R 4 , SO 2 NR 3 R 4 or C( ⁇ O)NR 3 R 4 in which R 2 , R 3 and R 4 are the same or different and are selected from: hydrogen, lower alkyl unsubstituted or substituted with one or several groups selected from halogen, OR 6 , COOR 6 or NR 6 R 7 in which R 6 and R 7 are the same or different and are selected from hydrogen or lower alkyl and,
  • R 6 and R 7 , and/or, R 3 and R 4 , together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N, and which may be substituted with,
  • a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or,
  • a lower alkyl optionally substituted with OR′, NR′R′′, C( ⁇ O)NR′R′′ or COOR′ in which R′ and R′′ are the same or different and are selected from,
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and,
  • R′ and R′′ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N;
  • X 4 is C—R 1 in which R 1 is selected from hydrogen, halogen, CN, NO 2 , SO 2 CH 3 , SO 3 H, CH 3 , CF 3 , OR 2 , SR 2 , NR 2 R 3 , COOR 2 , CONR 2 R 3 or SO 2 NR 2 R 3 in which R 2 and R 3 are the same or different and are selected from hydrogen or lower alkyl;
  • Z is chosen from O, S or NR 13 in which R 13 is hydrogen or CN;
  • A is a cycle chosen from:
  • a 1 , A 2 , A 3 , A 4 and A 5 are the same or different and are selected from:
  • a carbon atom unsubstituted or substituted with 1 or 2 groups, identical or different selected from lower alkyl, OH or F, or,
  • [0414] represents the carbon atom which is shared between the cycle A and the backbone cycle containing X and/or Y;
  • 2 atoms of the cycle A which are not adjacent, may be linked by a 2, 3 or 4 carbon atom chain;
  • a preferred group of compounds of formula (I) is a group in which X 1 , X 2 , X 3 , X 4 , X, Y, Z and A are as disclosed hereabove wherein when X 2 is C—R 1 and R 1 is X 5 —R 5 , then X 5 is not a single bond;
  • X 1 , X 2 and X 3 are the same or different and are C—R 1 , in which R 1 is selected from:
  • lower alkyl, lower alkenyl or lower alkynyl these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from halogen, CN, SO 3 H, OR 2 , COOR 2 , NR 3 R 4 , SO 2 NR 3 R 4 or C( ⁇ O)NR 3 R 4 in which R 2 ,
  • R 3 and R 4 are the same or different and are selected from hydrogen or lower alkyl, and,
  • R 3 and R 4 together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • X 4 is C—R 1 in which R 1 is selected hydrogen, halogen, CH 3 , CN, OR 2 , in which
  • R 2 is selected from hydrogen or lower alkyl
  • e) Z is chosen from O, S or NR 13 in which R 13 is hydrogen or CN; f) A is a cycle chosen from:
  • a 1 , A 2 A 3 , A 4 and A 5 are the same or different and are selected from carbon atoms, unsubstituted or substituted with CH 3 ;
  • [0432] represents the carbon atom which is shared between the cycle A and the backbone cycle containing X and/or Y;
  • 2 atoms of the cycle A which are not adjacent, may be linked by a 2, 3 or 4 carbon atom chain.
  • X 1 , X 2 , X 3 and X 4 are the same or different and are C—R 1 , in which R 1 is selected from:
  • X 5 is selected from
  • a lower alkylene optionally interrupted with 1 heteroatoms chosen from O, S and N
  • R 5 is selected from aryl, heteroaryl, cycloalkyl optionally interrupted with C( ⁇ O) or with 1, 2, or 3 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, cycloalkenyl optionally interrupted with C( ⁇ O) or with 1, 2, or 3 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, or a bicyclic group,
  • these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from Q3, heteroaryl or lower alkyl optionally substituted with Q3;
  • OR 2 OC( ⁇ O)R 2 , C( ⁇ O)OR 2 , SR 2 , S( ⁇ O)R 2 , C( ⁇ O)—NH—SO 2 —CH 3 , NR 3 R 4 , Q-R 2 , Q-NR 3 R 4 , NR 2 -Q-NR 3 R 4 or NR 3 -Q-R 2 in which Q is selected from C( ⁇ NR), C( ⁇ O), C( ⁇ S) or SO 2 , R is selected from hydrogen or lower alkyl and R 2 , R 3 and R 4 are the same or different and are selected from:
  • lower alkyl optionally interrupted with C( ⁇ O), Q4-aryl, Q4-heteroaryl, Q4-cycloalkyl optionally interrupted with C( ⁇ O) or with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, or Q4-cycloalkenyl optionally interrupted with C( ⁇ O) or with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, in which
  • Q4 is selected from (CH 2 ) n , lower alkyl interrupted with one heteroatom selected from O, S or N, lower alkenyl or lower alkynyl, these groups being optionally substituted with lower alkyl, OR′ or NR′R′′ in which R′ and R′′ are the same or different and are selected from hydrogen or lower alkyl;
  • n is an integer selected from 0, 1, 2, 3 or 4;
  • these groups being unsubstituted or substituted with 1 or 2 groups selected from lower alkyl, halogen, CN, CH 3 , SO 3 H, SO 2 CH 3 , CF 3 , C( ⁇ O)NH—SO 2 CH 3 , OR 6 , COOR 6 , C( ⁇ O)R 6 , NR 6 R 7 , C( ⁇ O)NR 6 R 7 or SO 2 NR 6 R 7 , in which R 6 and R 7 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with one or two groups selected from OR, COOR or NRR 8 in which R and R 8 are hydrogen or lower alkyl, and,
  • R 6 and R 7 , and/or, R 3 and R 4 , together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S, S( ⁇ O), SO 2 or N, and which may be substituted with,
  • a lower alkyl optionally substituted with OR′, NR′R′′, C( ⁇ O)NR′R′′ or COOR′ in which R′ and R′′ are the same or different and are selected from,
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and,
  • R′ and R′′ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N.
  • a preferred group of compounds of formula (I) is a group in which X 1 , X 2 , X 3 and X 4 , are as disclosed hereabove wherein when X 2 is C—R 1 and R 1 is X 5 —R 5 , then X 5 is not a single bond;
  • X 1 , X 2 , X 3 and X 4 are the same or different and are C—R 1 , in which R 1 is selected from:
  • lower alkyl or lower alkynyl these groups being unsubstituted or substituted with 1, 2 or 3 fluor atoms, OR 3 , COOR 3 or NR 3 R 4 in which R 3 and R 4 are the same or different and are selected from hydrogen or lower alkyl;
  • R 3 and R 4 together with the nitrogen atom to which they are linked, may also form a 6-membered heterocyclic ring, which may contain one or two heteroatoms selected from O or N;
  • OR 2 C( ⁇ O)OR 2 , NR 3 R 4 , C( ⁇ O)NR 3 R 4 or SO 2 NR 3 R 4 in which R 2 , R 3 l and R 4 are the same or different and are selected from:
  • these groups being unsubstituted or substituted with 1 or 2 groups selected from lower alkyl, CN, SO 3 H, C( ⁇ O)—NH—SO 2 —CH 3 , OR 6 , COOR 6 or NR 6 R 7 , in which R 6 and R 7 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with one or two groups selected from OR, COOR or NRR 8 in which R and R 8 are hydrogen or lower alkyl, and,
  • R 6 and R 7 , and/or, R 3 and R 4 , together with the nitrogen atom to which they are linked, can form a 4- to 6-membered heterocyclic ring, which may contain one or two heteroatoms selected from O or N, and which may be substituted with,
  • a 6-membered heterocyclic ring which may contain one or two heteroatoms selected from O or N and which may be substituted with a lower alkyl, or,
  • a lower alkyl optionally substituted with OR′, NR′R′′, C( ⁇ O)NR′R′′ or COOR′ in which R′ and R′′ are the same or different and are selected from,
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and,
  • R′ and R′′ together with the nitrogen atom to which they are linked, can form a 6-membered heterocyclic ring, which may contain one or two heteroatoms selected from O or N.
  • a preferred group of compounds of formula (I) is a group in which X 1 , X 2 X 3 and X 4 , are as disclosed hereabove wherein when X 2 is C—R 1 and R 1 is X 5 —R 5 , then X 5 is not a single bond;
  • a preferred group of compounds is the group in which one of X 1 , X 2 , X 3 and X 4 is C—R 1 in which R 1 is hydrogen while the others are identical or different and are C—R 1 in which R 1 is selected from:
  • X 5 is selected from:
  • a lower alkylene optionally interrupted with 1 heteroatoms chosen from O, S and N
  • R 5 is selected from aryl, heteroaryl, cycloalkyl optionally interrupted with C( ⁇ O) or with 1, 2, or 3 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, cycloalkenyl optionally interrupted with C( ⁇ O) or with 1, 2, or 3 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, or a bicyclic group, these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from Q3, heteroaryl or lower alkyl optionally substituted with Q3;
  • OR 2 OC( ⁇ O)R 2 , C( ⁇ O)OR 2 , SR 2 , S( ⁇ O)R 2 , C( ⁇ O)—NH—SO 2 —CH 3 , NR 3 R 4 , Q-R 2 , Q-NR 3 R 4 , NR 2 -Q-NR 3 R 4 or NR 3 -Q-R 2 in which Q is selected from C( ⁇ NR), C( ⁇ O), C( ⁇ S) or SO 2 , R is selected from hydrogen or lower alkyl and R 2 , R 3 and R 4 are the same or different and are selected from:
  • lower alkyl optionally interrupted with C( ⁇ O), Q4-aryl, Q4-heteroaryl, Q4-cycloalkyl optionally interrupted with C( ⁇ O) or with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, or Q4-cycloalkenyl optionally interrupted with C( ⁇ O) or with 1 or 2 heteroatoms chosen from O, S, S( ⁇ O), SO 2 or N, in which
  • Q4 is selected from (CH 2 ) n , lower alkyl interrupted with one heteroatom selected from O, S or N, lower alkenyl or lower alkynyl, these groups being optionally substituted with lower alkyl, OR′ or NR′R′′ in which R′ and R′′ are the same or
  • n is an integer selected from 0, 1, 2, 3 or 4;
  • these groups being unsubstituted or substituted with 1 or 2 groups selected from lower alkyl, halogen, CN, CH 3 , SO 3 H, SO 2 CH 3 , CF 3 , C( ⁇ O)—NH—SO 2 —CH 3 , OR 6 , COOR 6 , C( ⁇ O)R 6 , NR 6 R 7 , C( ⁇ O)NR 6 R 7 or SO 2 NR 6 R 7 , in which R 6 and R 7 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with one or two groups selected from OR, COOR or NRR 8 in which R and R 8 are hydrogen or lower alkyl, and,
  • R 6 and R 7 , and/or, R 3 and R 4 , together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S, S( ⁇ O), SO 2 or N, and which may be substituted with,
  • a lower alkyl optionally substituted with OR′, NR′R′′, C( ⁇ O)NR′R′′ or COOR′ in which R′ and R′′ are the same or different and are selected from,
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and,
  • R′ and R′′ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N.
  • a preferred group of compounds of formula (I) is a group in which X 1 , X 2 , X 3 and X 4 , are as disclosed hereabove wherein when X 2 is C—R 1 and R 1 is X 5 —R 5 , then X 5 is not a single bond;
  • a preferred group of compounds is the group in which one of X 1 , X 2 , X 3 and X 4 is C—R 1 in which R 1 is hydrogen while the others are identical or different and are C—R 1 in which R 1 is selected from:
  • lower alkyl or lower alkynyl these groups being unsubstituted or substituted with 1, 2 or 3 groups halogen or with OR 3 , COOR 3 or NR 3 R 4 in which R 3 and R 4 are the same or different and are selected from hydrogen or lower alkyl;
  • R 3 and R 4 together with the nitrogen atom to which they are linked, may also form a 6-membered heterocyclic ring, which may contain one or two heteroatoms selected from O or N;
  • OR 2 C( ⁇ O)OR 2 , NR 3 R 4 , C( ⁇ O)NR 3 R 4 or SO 2 NR 3 R 4 in which R 2 , R 3 and R 4 are the same or different and are selected from:
  • these groups being unsubstituted or substituted with 1 or 2 groups selected from lower alkyl, CN, SO 3 H, C( ⁇ O)—NH—SO 2 —CH 3 , OR 6 , COOR 6 or NR 6 R 7 , in which R 6 and R 7 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with one or two groups selected from OR, COOR or NRR 8 in which R and R 8 are hydrogen or lower alkyl, and,
  • R 6 and R 7 , and/or, R 3 and R 4 , together with the nitrogen atom to which they are linked, can form a 4- to 6-membered heterocyclic ring, which may contain one or two heteroatoms selected from O or N, and which may be substituted with,
  • a 6-membered heterocyclic ring which may contain one or two heteroatoms selected from O or N and which may be substituted with a lower alkyl, or,
  • a lower alkyl optionally substituted with OR′, NR′R′′, C( ⁇ O)NR′R′′ or COOR′ in which R′ and R′′ are the same or different and are selected from,
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and,
  • R′ and R′′ together with the nitrogen atom to which they are linked, can form a 6-membered heterocyclic ring, which may contain one or two heteroatoms selected from O or N.
  • a preferred group of compound is the group disclosed hereabove in which X 3 is C—R 1 in which R 1 is hydrogen.
  • X 3 is C—R 1 , in which R 1 is selected from:
  • R 5 is a single bond and R 5 is aryl, preferably phenyl or heteroaryl, preferably pyridyl, optionally substituted with one, two or three groups which are the same or different and which are selected from halogen, CN, CF 3 , SO 2 Me, OR 2 , COOR 2 , NR 2 R 3 , SO 2 NR 2 R 3 and CONR 2 R 3 in which R 2 and R 3 are the same or different and are selected from hydrogen and lower alkyl.
  • X 3 is C—R 1 , in which R 1 is selected from hydrogen or halogen, preferably Cl.
  • X 3 is C—R 1 in which R 1 is hydrogen.
  • X 4 is C—R 1 , in which R 1 is selected from
  • lower alkyl optionally substituted with OR 2 , COOR 2 or SO 2 NR 2 R 3 in which R 2 and R 3 are the same or different and are selected from hydrogen and lower alkyl.
  • X 4 is C—R 1 , in which R 1 is selected from hydrogen, halogen, CF 3 , methyl and methoxy.
  • X 1 is C—R 1 , in which R 1 is selected from
  • lower alkyl, Q4-aryl, Q4-heteroaryl, Q4-cycloalkyl optionally interrupted with C( ⁇ O) or with 1 or 2 heteroatoms chosen from O, S, or N
  • Q4-cycloalkenyl optionally interrupted with C( ⁇ O) or with 1 or 2 heteroatoms chosen from O, S, or N, in which
  • Q4 is selected from (CH 2 ) n , lower alkyl interrupted with one heteroatom selected from O, S or N, lower alkenyl or lower alkynyl;
  • n is an integer selected from 0,1, 2 or 3;
  • R 6 and R 7 are the same or different and are selected from hydrogen or lower alkyl, optionally substituted with NH 2 , COOH, OH;
  • R 6 and R 7 together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N and which may be substituted with,
  • COR′ or lower alkyl optionally substituted with OR′, NR′R′′, C( ⁇ O)NR′R′′ or COOR′ in which R′ and R′′ are the same or different and are selected from hydrogen or lower alkyl;
  • lower alkyl optionally substituted with CN, SO 3 H, OR 3 , NR 3 R 4 , COOR 3 or CONR 3 R 4 in which R 3 and R 4 are the same or different and are selected from
  • lower alkyl optionally substituted with OH, COOH or NH 2
  • X 5 is a lower alkylene optionally interrupted with a heteroatom selected O and N and R 5 is selected from aryl, heteroaryl, cycloalkyl optionally interrupted with C( ⁇ O) or with 1, 2, or 3 heteroatoms chosen from O, S or N and cycloalkenyl optionally interrupted with C( ⁇ O) or with 1, 2, or 3 heteroatoms chosen from O, S or N,
  • R 3 and R 4 together with the nitrogen atom to which they are linked, can form a 4- to 6-membered heterocyclic ring, which may contain one or two heteroatoms selected from O or N, and which may be substituted with,
  • X 1 is C—R 1 , in which R 1 is selected from hydrogen, halogen, preferably Cl or Br, or OR 2 in which R 2 is selected from
  • Q4-oxadiazole, Q4-tetrazole, Q4-morpholine, Q4-furan, Q4-isoxazole in which Q4 is selected from lower alkyl interrupted with one heteroatom selected from O, S or N and (CH 2 ) n in which n is an integer selected from 1 and 2;
  • X 2 is C—R 1 , in which R 1 is X 5 —R 5 , in which
  • X 5 is a single bond
  • R 5 is phenyl or pyridyl
  • a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or,
  • a lower alkyl optionally substituted with OR′, NR′R′′, C( ⁇ O)NR′R′′ or COOR′ in which R′ and R′′ are the same or different and are selected from,
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and,
  • R′ and R′′ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N.
  • X 2 is C—R 1 , in which R 1 is X 5 —R 5 , in which
  • X 5 is a single bond
  • R 5 is phenyl
  • a 6-membered heterocyclic ring which may contain one or two nitrogen atoms and which may be substituted with a lower alkyl, or,
  • a lower alkyl optionally substituted with OR′, NR′R′′, C( ⁇ O)NR′R′′ or COOR′ in which R′ and R′′ are the same or different and are selected from,
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and,
  • R′ and R′′ together with the nitrogen atom to which they are linked, can form a 6-membered heterocyclic ring, which may contain one or two heteroatoms selected from O or N;
  • compounds of the invention are compounds of formula (I).
  • X is NH
  • Y is NH
  • Z is O.
  • X is NH
  • Y is NH
  • Z is O
  • A is selected from cyclohexyl or cycloheptyl, optionally interrupted with C( ⁇ O) or 0, and unsubstituted or substituted with CH 3 , OH or OCH 3 .
  • A is selected from unsubstituted cyclohexyl or cycloheptyl.
  • A is unsubstituted cyclohexyl.
  • X is NH
  • Y is NH
  • Z is O
  • A is unsubstituted cyclohexyl.
  • X is NH
  • Y is NH
  • Z is O
  • A is unsubstituted cyclohexyl
  • X 3 is C—R 1 in which R 1 is hydrogen and X 4 is C—R 1 , in which R 1 is selected from hydrogen, halogen, CF 3 , methyl or methoxy.
  • Halogen includes fluoro, chloro, bromo, and iodo. Preferred halogens are F and Cl.
  • Lower alkyl includes straight and branched carbon chains having from 1 to 6 carbon atoms. Examples of such alkyl groups include methyl, ethyl, isopropyl, tert-butyl and the like.
  • Lower alkenyl includes straight and branched hydrocarbon radicals having from 2 to 6 carbon atoms and at least one double bond. Examples of such alkenyl groups are ethenyl, 3-buten-1-yl, 2-ethenylbutyl, 3-hexen-1-yl, and the like.
  • Lower alkynyl includes straight and branched hydrocarbon radicals having from 2 to 6 carbon atoms and at least one triple bond. Examples of such alkynyl groups are ethynyl, 3-butyn-1-yl, propynyl, 2-butyn-1-yl, 3-pentyn-1-yl, and the like.
  • Lower haloalkyl includes a lower alkyl as defined above, substituted with one or several halogens.
  • a preferred haloalkyl is trifluoromethyl.
  • Aryl is understood to refer to an aromatic carbocycle containing between 6 and 10, preferably 6, carbon atoms.
  • a preferred aryl group is phenyl.
  • Heteroaryl includes aromatic cycles which have from 5 to 10 ring atoms, from 1 to 4 of which are independently selected from the group consisting of O, S, and N.
  • Preferred heteroaryl groups have 1, 2, 3 or 4 heteroatoms in a 5- or 6-membered aromatic ring. Examples of such groups are tetrazole, pyridyl, thienyl and the like.
  • Preferred cycloalkyl contain from 3 to 8 carbon atoms. Examples of such groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
  • interrupted means that in a backbone chain, a carbon atom is replaced by an heteroatom or a group as defined herein.
  • cycloalkyl or cycloalkenyl optionally interrupted with C( ⁇ O) or with 1 heteroatom chosen from O, S, S( ⁇ O), SO 2 or N the term “interrupted” means that C( ⁇ O) or a heteroatom can replace a carbon atom of the ring.
  • Example of such groups are morpholine or piperazine.
  • Cycloalkenyl includes 3- to 10- membered cycloalkyl containing at least one double bond.
  • Heterocyclic ring include heteroaryl as defined above and cycloalkyl or cycloalkenyl, as defined above, interrupted with 1, 2 or 3 heteroatoms chosen from O, S, S( ⁇ O), SO 2 , or N.
  • Bicyclic substituents refer to two cycles, which are the same or different and which are chosen from aryl, heterocyclic ring, cycloalkyl or cycloalkenyl, fused together to form said bicyclic substituents.
  • a preferred bicyclic substituent is indolyl.
  • Sp 2 hybridization state carbon atoms in an Sp 2 hybridization state are trigonal instead of tetraedric. It means that the carbon atoms in a SP 2 hybridization state are linked to three atoms and form a double bond with one of these three atoms.
  • Preferred compounds are:
  • One method for preparing a compound of the formula (I) defined above in which Y is N—R 12 , X is N—R 9 and Z is O comprises reacting a substituted urea of formula
  • the compounds utilized in the invention include pharmaceutically acceptable derivatives of compounds of formula (I), (II) or (III) such as solvates, hydrates, pharmaceutically acceptable salts and polymorphs (different crystalline lattice descriptors).
  • compositions having a basic part include salts having a basic part and salts having an acidic part.
  • the expression pharmaceutically acceptable salt of a compound of formula (I), (II) or (III) having a basic part should be understood to refer to the addition salts of the compounds of formula (I), (II) or (III) which may be formed from non-toxic inorganic or organic acids such as, for example, hydrobromic, hydrochloric, sulfuric, phosphoric, nitric, acetic, succinic, tartaric, citric, maleic, hydroxymaleic, benzoic, fumaric and toluenesulfonic acid salts, and the like.
  • the various quaternary ammonium salts of the derivatives (I), (II) or (III) are also included in this category of compounds of the invention.
  • the expression pharmaceutically acceptable salt of a compound of formula (I), (II) or (III) having an acidic part is understood to refer to the usual salts of the compounds of formula (I), (II) or (III) which may be formed from non-toxic inorganic or organic bases such as, for example, the hydroxides of alkali metals and alkaline-earth metals (sodium, potassium, magnesium and calcium), amines (dibenzylethylenediamine, trimethylamine, piperidine, pyrrolidine, benzylamine and the like) or alternatively quaternary ammonium hydroxides such as tetramethylammonium hydroxide. (See also “Pharmaceutical salts” by Berge S. M. et al. (1997) J. Pharm. Sci. 66: 1-19, which is incorporated herein by reference.).
  • compositions which are appropriate for the nature, and severity of the complaint to be treated.
  • the daily dose in humans is usually between 1 mg and 1 g of product, which may be taken in one or more individual doses.
  • compositions are prepared in forms which are compatible with the intended route of administration, such as, for example, tablets, coated tablets, capsules, mouthwashes, aerosols, powders for inhalation, suppositories, enemas, foams (such as rectal foams) gels or suspensions.
  • compositions are prepared by methods which are familiar to those skilled in the art and comprise from 0.5 to 60% by weight of active principle (compound of the invention) and 40 to 99.5% by weight of a pharmaceutical vehicle or carrier which is appropriate and compatible with the active principle and the physical form of the intended composition.
  • Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.
  • a solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.
  • the carrier is a finely divided solid, which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
  • the powders, tablets, cachets or encapsulated forms for capsules preferably contain 5% to about 70% of the active component.
  • Suitable carriers are magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.
  • Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.
  • the drug may be delivered as a spray (either in a pressurized container fitted with an appropriate valve or in a non-pressurized container fitted with a metering valve).
  • Liquid form preparations include solutions, suspensions, and emulsions.
  • Sterile water or water-propylene glycol solutions of the active compounds may be mentioned as an example of liquid preparations suitable for parenteral administration.
  • Liquid preparations can also be formulated in solution in aqueous polyethylene glycol solution.
  • Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavouring agents, stabilizers, and thickening agents as desired.
  • Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.
  • a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized molds and allowed to cool and solidify. Enemas are obtained according to known procedures to prepare solutions adapted for rectal administration. Foams are prepared according to known methods (these foams can notably be similar to those used to administer a drug such as 5-ASA for treating rectocolite).
  • the pharmaceutical preparation is in unit dosage form.
  • the preparation is divided into unit doses containing appropriate quantities of drug.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparation, for example, packaged tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms.
  • the compounds of the invention are PDE inhibitors, and particularly PDE7 inhibitors. These compounds have low IC 50 values, typically at most 5 ⁇ M, preferably below 1 ⁇ M, and even below 100 nM.
  • selective PDE7 inhibitors refers to a compound which have an IC 50 for PDE7 at least 5 times lower than the IC 50 for a PDE distinct from PDE7, and preferably at least 10 times, 15 times, 20 times, 30 times, 40 times, 50 times or 100 times lower than the IC 50 value for a PDE distinct from PDE7.
  • a PDE distinct from PDE7 refers preferably to a PDE chosen from PDE1, PDE3, PDE4 or PDE5.
  • the compounds of the invention and more particularly the family of compounds given as examples in the present description, have an IC 50 value for the enzyme PDE7 which is often 100 times lower than the value of their IC 50 for a PDE distinct from PDE7, in particular PDE1, PDE3, PDE4 or PDE5.
  • Compounds of the invention can be used in the treatment of various diseases, as they can modulate inflammatory and immunological processes due to the increase of intracellular cAMP levels.
  • the diseases that can be treated are T-cell-related diseases, AE-cell-related diseases and immune disorders, such as autoimmune diseases, osteoarthritis, rheumatoid arthritis, multiple sclerosis, osteoporosis, asthma, COPD, cancer, AIDS, inflammation, allergy and various inflammatory disorders such as, for example, inflammatory bowel disease (IBD).
  • T-cell-related diseases such as autoimmune diseases, osteoarthritis, rheumatoid arthritis, multiple sclerosis, osteoporosis, asthma, COPD, cancer, AIDS, inflammation, allergy and various inflammatory disorders such as, for example, inflammatory bowel disease (IBD).
  • IBD inflammatory bowel disease
  • the invention finally relates to a method for the treatment of the above-mentioned diseases comprising administering to a mammal, particularly a human, in need thereof an effective amount of compound of the invention.
  • the compounds according to the present invention can be obtained by carrying out several synthetic processes. Some of these synthetic processes (protocols A-L) are described below.
  • the starting materials are either commercially available or can be prepared according to routes known to the skilled person. If the starting urea in step 3 is not commercially available, it can be prepared by treating the corresponding isocyanate with a primary amine in a solvent such as tetrahydrofuran (step 1) or treating the corresponding aniline with a substituted isocyanate in an organic solvent such as dichloromethane or acetonitrile (step 2).
  • step 3 the urea is converted into the desired quinazolinone by reacting it with a cyclic ketone in polyphosphoric acid at 80-130° C.
  • X 1 , X 2 , X 3 , X 4 , A and R 9 are as defined in the summary of the invention, Y may be O, S or NH and LG is a leaving group and R is lower alkyl.
  • the starting compounds are either commercially available or can be prepared according to routes known to the skilled person.
  • step 1 compound (2a) is reacted with dialkyl-carbamoyl chloride to form the desired N,N dialkyl-carbamate or thiocarbamate according to routes known to the skilled person. See Poirier, M.; Simard, M.; Wuest, J. D.; Organometallics, 1996, 15 (4), 1296-1300.
  • oxygen-based directed metalation groups such as OMe, OMOM, OP(OR 2 ), OPO(NMe) 2 . See Snieckus, Chem. Rev., 1990, 90, 879-933.
  • aniline derivative is protected as a t-butyl carbamate or as a pivaloyl amide according to routes known to the skilled person. See Tet Lett., 1994, 35(48), 9003-9006.
  • step 2 compound ( 2b ) is converted to a lithium salt (when Y is O or S) or to a dilithium salt thereof by reaction with an excess of lithium compound-forming agent such as t-butyllithium in a mixed solvent of anhydrous ether (for example, diethyl ether and tetrahydrofuran) and alkane (for example pentane), and reacted with an appropriate ketone.
  • the reaction is carried out at low temperature (between ⁇ 78° C. and 0° C. to give the expected tertiary entity.
  • the organolithium intermediate can also be formed by halogen-metal exchange.
  • the organolithium can also be transmetallated into another organometallic reagent such as a cerate (with anhydrous cerium trichloride for example) prior to treatment with the ketone.
  • the protecting group is removed according to routes known to the skilled person either under reductive conditions (when Y ⁇ O—P or S—P), under acidic condition or under basic condition to give compound ( 2d ).
  • step 4 compound ( 2d ) is reacted with an appropriate substituted isocyanate to obtain compound ( 2e ).
  • step 5 treating compound ( 2e ) with an acid (mineral acid or lewis acid) triggers cyclisation to give compound ( 2f ).
  • an acid mineral acid or lewis acid
  • X 1 , X 2 , X 3 , X 4 and A are as defined in the summary of the invention
  • Y may be O, S or NR 2
  • X may be O
  • S NR 9 and LG is a leaving group
  • Z′ may be OR, SR, NR 16 R 17 or NR 13
  • Hal is halogen
  • Z 2 may be O or S and where R 12 , R 13 , R 16 , R 17 and R 9 are as defined in the summary of the invention and R is alkyl or benzyl.
  • step 1 intermediate 2d obtained according to protocol B is reacted either with a carbonyl derivative such as a carbonate, a chloroformate, an isocyanate; a thiocarbonyl derivative such as an isothiocyanate, a thionochloroformate, or others such as cyanamide, 3,5-dimethyl-1H-pyrazole-1-carboximidamide nitrate, S-methylisothiourea or equivalent.
  • a carbonyl derivative such as a carbonate, a chloroformate, an isocyanate
  • a thiocarbonyl derivative such as an isothiocyanate, a thionochloroformate, or others
  • cyanamide 3,5-dimethyl-1H-pyrazole-1-carboximidamide nitrate, S-methylisothiourea or equivalent.
  • intermediate 2′e can be prepared in two steps by treating 2d with either cyanogens bromide or a carbonyl (or thiocarbonyl) derivative activated by two leaving groups such as phosgene (or thiophosgene), 1,1′-carbonyldiimidazole (or 1,1′-thiocarbonyldiimidazole), nitrophenylchloroformate or carbon disulfide, followed by addition of a nucleophile such as an amine, an alcohol or a thiol to introduce Z′.
  • a nucleophile such as an amine, an alcohol or a thiol
  • intermediates 2e obtained can be derivatized into other intermediates 2e according to routes known to the skilled person.
  • an intermediate thiourea 2e wherein Y ⁇ NH, X ⁇ S and Z′ ⁇ NH 2 can be treated with an alkyl halide R—X according to reaction conditions known to the skilled person to give an intermediate 2e wherein Y ⁇ NH, X ⁇ NH and Z′ ⁇ SR.
  • step 2 intermediate 2e is treated with a source of halonium such as iodine, N-iodosuccinimide, bromine or N-bromosuccinimide to yield intermediate 2′f .
  • a source of halonium such as iodine, N-iodosuccinimide, bromine or N-bromosuccinimide
  • intermediate 2f can be derivatized into different intermediates 2′f according to routes known to the skilled person.
  • the halide 2f can be reduced to 2g as shown in step 3 under reaction conditions known to the skilled person, such as treatment with trialkyl tin hydride and a radical initiator like azobisisobutyronitrile (AIBN) in an inert organic solvent.
  • AIBN azobisisobutyronitrile
  • intermediate 2e could be directly transformed into 2g under acidic treatment according to conditions that can be determined by the skilled person. If necessary, intermediate 2′g can also be derivatized into different 2′g according to routes known to the skilled person.
  • Z′ is OR or SR
  • intermediate 2q ′ can be converted to 2′h as shown in step 4. This can be done according to conditions known to the skilled person by hydrolysis under aqueous acidic media or by hydrogenolysis when R is benzyl.
  • X 1 , X 2 , X 3 , X 4 and A are as defined in the summary of the invention, R 9 is alkyl, aryl, alkylsulfonyl or arylsulfonyl, R is lower alkyl and Y may be O, S or NH.
  • step 1 compound ( 3a ) is converted to a lithium salt (when Y is O or S) or to a dilithium salt (when Y is NH) thereof by reaction with an excess of lithium 15 compound-forming agent such as t-butyllithium in a mixed solvent of anhydrous ether (for example, diethyl ether and tetrahydrofuran) and alkane (for example pentane).
  • anhydrous ether for example, diethyl ether and tetrahydrofuran
  • alkane for example pentane
  • the resulting organolithium is reacted with an appropriate imine at low temperature to give the expected tertiary amine ( 3b ).
  • the organolithium can also be transmetallated into another organometallic reagent such as a cerate (with anhydrous cerium trichloride for example) prior to treatment with the ketone.
  • step 2 the protecting group is removed according to routes known to the skilled person either under reductive conditions (when Y ⁇ O—P or S—P), under acidic condition or under basic condition to give compound ( 3c ).
  • R 9 is alkyl or arylsulfonyl
  • this group can be deprotected into the NH derivative by reductive methods or hydrolysis according to methods known to the skilled person.
  • step 3 compound ( 3c ) is reacted with a compound selected from a carbonic acid halide such as phosgene a carbonic acid diester, 1,1′-carbonyldiimidazole and so on to obtain compound ( 3d ).
  • step 4 compound (3c) is reacted with an orthoester, in the presence of an acid to obtain compound (3e) or its tautomeric forms.
  • X 1 , X 2 , X 3 , X 4 , A, R 9 and R 12 are as defined in the summary of the invention, Z is O or S.
  • the starting materials are either commercially available or can be prepared according to routes known to the skilled person.
  • step 1 the starting anthranilic acid is treated with phosgene or an equivalent source of carbonyl such as triphosgene or carbonyl diimidazole.
  • phosgene or an equivalent source of carbonyl such as triphosgene or carbonyl diimidazole.
  • Various solvents and reaction conditions can be used and will be easily determined by the skilled person.
  • the resulting isatoic anhydride is treated with the Grignard reagent obtained from a dihalide and magnesium in a solvent such as tetrahydrofuran or ether (step 2).
  • step 3 the aniline is converted to an urea by treatment with a substituted isocyanate.
  • Various solvents and reaction conditions can be used and will be easily determined by the skilled person.
  • the reaction can be performed at room temperature or reflux in an inert solvent such as dichloromethane, acetonitrile or tetrahydrofuran in the presence or not of a base such as triethylamine or pyridine.
  • a base such as triethylamine or pyridine.
  • the resulting hydroxy-urea is subjected to an acid with or without an organic solvent.
  • the reaction can be carried out at 70-90° C. in sulfuric acid.
  • a solvent such as toluene or acetic acid may be added.
  • step 3′ compound 4c is converted to compound 4f by treatment with a carbonyl (or thiocarbonyl) derivative activated by two leaving groups such as phosgene (or thiophosgene), 1,1′-carbonyldiimidazole (or 1,1′-thiocarbonyldiimidazole).
  • a carbonyl (or thiocarbonyl) derivative activated by two leaving groups such as phosgene (or thiophosgene), 1,1′-carbonyldiimidazole (or 1,1′-thiocarbonyldiimidazole).
  • X 1 , X 3 , X 4 , X, Y and A are as defined in the summary of the invention.
  • the starting tricyclic compound is reacted with an electrophile E + such as halonium or acylium in presence or not of an activating agent in an organic solvent.
  • an electrophile E + such as halonium or acylium
  • the starting material can be treated with a source of halonium such as N-iodo or N-bromosuccinimide in dimethylformamide at 60-70° C. to give the corresponding halide.
  • the starting material can be reacted with an acyl halide and aluminium trichloride, as Lewis acid, in a solvent such as dichloroethane at 80° C.
  • X 1 , X 2 , X 3 and X 4 , X, Y, Z and A are as defined in the summary of the invention, R is alkenyl, alkynyl, aryl or heteroaryl and R′ is H or alkyl.
  • the starting aryl or heteroaryl iodide or bromide is subjected to a palladium-catalyzed cross-coupling reaction with an organometallic species, such as a boronate ester, a boronic acid, an organozinc (Hal ⁇ halogen) or a trialkylstannane in the presence of base when needed.
  • organometallic species such as a boronate ester, a boronic acid, an organozinc (Hal ⁇ halogen) or a trialkylstannane in the presence of base when needed.
  • the organometallic species can be replaced with a terminal alkene or alkyne in the coupling reaction.
  • a source of copper(l) such as copper iodide
  • Various palladium catalysts, solvents and reaction conditions can be used for these coupling reactions and will be easily determined by the skilled person.
  • the starting aryl or heteroaryl iodide or bromide can be reacted with a boronic acid in dimethylformamide at 80° C. in the presence of tetrakis(triphenylphosphine)palladium as catalyst and an aqueous solution of potassium carbonate as a base.
  • X 1 , X 2 , X 3 , X 4 , X, Y, Z, R 2 , R 3 , R 4 and A are as defined in the summary of the invention and R is selected from aryl, alkenyl, alkynyl or heteroaryl.
  • step 1 the starting aryl or heteroaryl iodide or bromide is treated with bis(pinacolato)diboron under palladium catalysis to give the corresponding boronate ester.
  • Various paladium catalysts, solvents and reaction conditions can be used and will be easily determined by the skilled person.
  • the starting heteroaryl iodide or bromide can be reacted with bis(pinacolato)diboron in dimethylformamide at 80° C. in the presence of tetrakis(triphenylphosphine) palladium as catalyst.
  • the resulting boronate ester is then coupled to an aryl, alkenyl, alkynyl or heteroaryl iodide, bromide or triflate catalyzed by a palladium species (step 2).
  • a palladium species e.g., various paladium catalysts, solvents and reaction conditions can be used for this coupling reactions and will be easily determined by the skilled person.
  • the boronate ester is reacted with an aryl, alkenyl, alkynyl or heteroaryl iodide in dimethylformamide at 80° C. in the presence of sodium acetate as base and tetrakis(triphenylphosphine)palladium as catalyst to give the coupled product.
  • step 3 the boronate ester is hydrolyzed to the corresponding boronic acid. This can be done by treating it with acid, e.g. an aqueous solution of hydrochloric acid, in an organic solvent, e.g. methanol. The resulting boronic acid is coupled,
  • step 4 under air with a phenol or heteroaryl alcohol, or,
  • step 5 with a primary or secondary amine, heteroarylamine, aniline, amide, sulfonamide, urea, carbamate or imide,
  • step 1 urea, carbamate or thio carbamate is initially converted into a halo-imine via a chlorinating agent such as POCl 3 which is then further reacted (step 2) with a suitable amine to form the final compound.
  • the reaction can be carried out without solvent or in a solvent, for example an alcohol such as ethanol, at a temperature between 40 and 80° C. or under pressure for volatile amine, for example.
  • step 3 the halo-imine is transformed into thio-derivative with thiourea.
  • the process of scheme 9 above can also be applied to compounds of formula (I) in which Y is NH and X is N—R 9 .
  • X 1 , X 2 , X 3 , X 4 , R 9 , R 12 and A are as defined in the summary of the invention and LG is a leaving group such as trifuoromethane sulfonate, mesylate or halogen.
  • step 1 the quinazolinone is reacted with R 12 -LG to obtain the N-substituted quinazoline
  • step 2 the N-substituted quinazolinone is reacted with R 9 -LG.
  • Step 2 of the above process can also be applied to compounds of formula (I) in which Y is O or S.
  • Step 1 of the above process can also be applied to compounds of formula (I) in which X is O or S.
  • X 1 , X 2 , X 3 , X 4 , R 9 and A are as defined in the summary of the invention and LG is a leaving group such as trifuoromethane sulfonate, mesylate or halogen.
  • step 1 the quinazolinone is reacted with paramethoxy-benzyl chloride (PMB).
  • PMB paramethoxy-benzyl chloride
  • Other protecting group can be used.
  • Various solvents, operating conditions, bases, can be used and will be easily determined by the skilled person. For example, and without any limitation, one can use for the reaction cesium carbonate as base in dimethylformamide as solvent.
  • step 2 the protected quinazolinone is reacted with R 9 -LG.
  • Various solvents, operating conditions, bases can be used and will be easily determined by the skilled person. For example, and without any limitation, one can use for the reaction sodium hydride as base in dimethylformamide as solvent.
  • step 3 treatment of the N1-PMB protected quinazolinone with TFA removed the protecting group.
  • Other protecting groups and deprotecting conditions can be used.
  • X 2 , X 3 , X 4 , and A and Y are as defined in the summary of the invention, R is alkyl or C( ⁇ O)-alkyl and LG is a leaving group.
  • step 1 the starting methoxy derivative is demethylated with boron tribromide in a solvent such as dichloromethane.
  • a solvent such as dichloromethane.
  • the resulting phenol intermediate is treated in step 2 with an electrophile such as an alkyl halide, an acyl halide or the like in the presence of a base such as potassium carbonate, cesium carbonate or sodium hydride in a solvent like dimethylformamide.
  • an electrophile such as an alkyl halide, an acyl halide or the like in the presence of a base such as potassium carbonate, cesium carbonate or sodium hydride in a solvent like dimethylformamide.
  • Examples 1 to 100 illustrate, without limiting it, the synthesis of particularly active compounds of formula (I) according to the invention.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
US10/101,996 2001-03-21 2002-03-19 Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors Abandoned US20020198198A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/852,404 US7214676B2 (en) 2001-03-21 2004-05-24 Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US11/551,687 US20070049558A1 (en) 2001-03-21 2006-10-20 New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP01/03355 2001-03-21
PCT/EP2001/003355 WO2002076953A1 (en) 2001-03-21 2001-03-21 New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/852,404 Continuation US7214676B2 (en) 2001-03-21 2004-05-24 Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors

Publications (1)

Publication Number Publication Date
US20020198198A1 true US20020198198A1 (en) 2002-12-26

Family

ID=8164349

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/101,996 Abandoned US20020198198A1 (en) 2001-03-21 2002-03-19 Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US10/852,404 Expired - Fee Related US7214676B2 (en) 2001-03-21 2004-05-24 Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US11/551,687 Abandoned US20070049558A1 (en) 2001-03-21 2006-10-20 New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/852,404 Expired - Fee Related US7214676B2 (en) 2001-03-21 2004-05-24 Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US11/551,687 Abandoned US20070049558A1 (en) 2001-03-21 2006-10-20 New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors

Country Status (47)

Country Link
US (3) US20020198198A1 (ru)
EP (2) EP1801106A3 (ru)
JP (1) JP4086663B2 (ru)
KR (1) KR100617435B1 (ru)
CN (1) CN100447136C (ru)
AP (1) AP1699A (ru)
AR (1) AR033617A1 (ru)
AT (1) ATE367381T1 (ru)
AU (1) AU2002304800B2 (ru)
BG (1) BG108181A (ru)
BR (1) BR0208192A (ru)
CA (1) CA2441313C (ru)
CU (1) CU23218A3 (ru)
CY (1) CY1106829T1 (ru)
CZ (1) CZ20032451A3 (ru)
DE (1) DE60221233T2 (ru)
DK (1) DK1373224T3 (ru)
EA (1) EA006815B1 (ru)
EC (1) ECSP034750A (ru)
EE (1) EE200300459A (ru)
ES (1) ES2288552T3 (ru)
GE (1) GEP20053631B (ru)
GT (1) GT200200053A (ru)
HK (1) HK1061854A1 (ru)
HR (1) HRP20030740A2 (ru)
HU (1) HUP0303637A3 (ru)
IL (2) IL157659A0 (ru)
IS (1) IS2529B (ru)
MA (1) MA27001A1 (ru)
MX (1) MXPA03008485A (ru)
MY (1) MY142045A (ru)
NO (1) NO326086B1 (ru)
NZ (1) NZ527847A (ru)
OA (1) OA12454A (ru)
PA (1) PA8541601A1 (ru)
PE (1) PE20021010A1 (ru)
PL (1) PL367058A1 (ru)
PT (1) PT1373224E (ru)
RS (1) RS50429B (ru)
SI (1) SI1373224T1 (ru)
SK (1) SK11562003A3 (ru)
SV (1) SV2003000925A (ru)
TN (1) TNSN03076A1 (ru)
TW (1) TWI267509B (ru)
UA (1) UA74243C2 (ru)
WO (2) WO2002076953A1 (ru)
ZA (1) ZA200306601B (ru)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106631A1 (en) * 2002-09-17 2004-06-03 Patrick Bernardelli Spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
US20080064671A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
WO2008119057A2 (en) 2007-03-27 2008-10-02 Omeros Corporation The use of pde7 inhibitors for the treatment of movement disorders
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US20100113486A1 (en) * 2007-03-27 2010-05-06 Omeros Corporation Use of pde7 inhibitors for the treatment of movement disorders
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2258358A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A2 (en) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2011063115A1 (en) 2009-11-19 2011-05-26 Braincells Inc. Combination of nootropic agent with one or more neurogenic or neurogenic sensitizing agents for stimulating or increasing neurogenesis
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2011091033A1 (en) 2010-01-20 2011-07-28 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2012064667A2 (en) 2010-11-08 2012-05-18 Omeros Corporation Treatment of addiction and impulse-control disorders using pde7 inhibitors
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
US11685745B2 (en) 2017-07-12 2023-06-27 Dart Neuroscience, Llc Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors
WO2024038089A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0230195D0 (en) * 2002-12-24 2003-02-05 Biofocus Plc Compound Libraries
EP2617419A1 (en) 2003-04-24 2013-07-24 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metallproteases
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
EP1656145A1 (en) * 2003-08-12 2006-05-17 F. Hoffmann-La Roche Ag Spiro-substituted tetrahydroquinazolines as corticotropin releasing factor (cfr) antagonists
EP2433943B1 (en) 2004-07-01 2013-09-11 Daiichi Sankyo Company, Limited Intermediates for thienopyrazole derivatives having PDE7 inhibitory activity
US20090111837A1 (en) * 2005-03-01 2009-04-30 Peter Cox Use of pde7 inhibitors for the treatment of neuropathic pain
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
GB0504209D0 (en) * 2005-03-01 2005-04-06 Pfizer Ltd New use of PDE7 inhibitors
KR100680497B1 (ko) * 2005-07-25 2007-02-08 엘지전자 주식회사 근거리통신 시스템에서 단말기가 액세스 포인트에 접속하는방법
KR20080065704A (ko) 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 의학적 이상의 치료 방법들, 조성물들, 및 키트들
RS20080233A (en) 2005-12-02 2009-07-15 Pfizer Limited, Spirocyclic quinazoline derivatives as pde7 inhibitors
CA2687944A1 (en) * 2007-05-24 2008-11-27 Pfizer Limited Spirocyclic quinazoline derivatives and their use as pde7 inhibitors
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2014007951A2 (en) 2012-06-13 2014-01-09 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
DK2986610T5 (en) 2013-04-19 2018-12-10 Incyte Holdings Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
NZ773116A (en) 2015-02-20 2024-05-31 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
CA3008689A1 (en) * 2015-12-16 2017-06-22 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pyrido[1,2-a]pyrimidone analog, crystal form thereof, intermediate thereof and preparation method therefor
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN107382976A (zh) * 2017-07-04 2017-11-24 孙秀芹 一种治疗盆腔炎的化合物及制备方法和应用
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
BR112022007163A2 (pt) 2019-10-14 2022-08-23 Incyte Corp Heterociclos bicíclicos como inibidores de fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5815979A (ja) 1981-07-11 1983-01-29 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体およびその製造法
US4764512A (en) 1986-08-27 1988-08-16 Rorer Pharmaceutical Corporation Benzodiazinone-pyridone compounds, cardiotonic compositions including the same, and their uses
GR1000821B (el) * 1988-11-22 1993-01-25 Tanabe Seiyaku Co Μεθοδος παραγωγης παραγωγων κιναζολινονης.
WO1994013696A1 (en) 1992-12-11 1994-06-23 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
US5602143A (en) * 1994-12-08 1997-02-11 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
SK45898A3 (en) * 1995-10-17 1999-01-11 Astra Pharma Prod Pharmaceutically active quinazoline compounds
CN1205008A (zh) * 1996-08-30 1999-01-13 协和发酵工业株式会社 咪唑并喹唑啉衍生物
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
WO2000066560A1 (en) * 1999-05-04 2000-11-09 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
JP2002543155A (ja) 1999-05-04 2002-12-17 ワイス 抗プロゲスチン及びプロゲスチンを含有する避妊組成物
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
AU2274101A (en) 1999-12-21 2001-07-03 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106631A1 (en) * 2002-09-17 2004-06-03 Patrick Bernardelli Spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
US7429598B2 (en) * 2002-09-17 2008-09-30 Warner-Lambert Company Spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
EP2258358A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A2 (en) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2275095A2 (en) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2258357A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
EP2377530A2 (en) 2005-10-21 2011-10-19 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2382975A2 (en) 2006-05-09 2011-11-02 Braincells, Inc. Neurogenesis by modulating angiotensin
US20080064671A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
WO2008119057A2 (en) 2007-03-27 2008-10-02 Omeros Corporation The use of pde7 inhibitors for the treatment of movement disorders
US20110091388A1 (en) * 2007-03-27 2011-04-21 Omeros Corporation Use of pde7 inhibitors for the treatment of movement disorders
US20100113486A1 (en) * 2007-03-27 2010-05-06 Omeros Corporation Use of pde7 inhibitors for the treatment of movement disorders
US20080260643A1 (en) * 2007-03-27 2008-10-23 Omeros Corporation Use of pde7 inhibitors for the treatment of movement disorders
US9119822B2 (en) 2007-03-27 2015-09-01 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011063115A1 (en) 2009-11-19 2011-05-26 Braincells Inc. Combination of nootropic agent with one or more neurogenic or neurogenic sensitizing agents for stimulating or increasing neurogenesis
WO2011091033A1 (en) 2010-01-20 2011-07-28 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2012064667A2 (en) 2010-11-08 2012-05-18 Omeros Corporation Treatment of addiction and impulse-control disorders using pde7 inhibitors
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
US11207275B2 (en) 2010-11-08 2021-12-28 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
US11464785B2 (en) 2010-11-08 2022-10-11 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
EP4275752A2 (en) 2010-11-08 2023-11-15 Omeros Corporation Treatment of addiction and impulse-control disorders using pde7 inhibitors
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US11685745B2 (en) 2017-07-12 2023-06-27 Dart Neuroscience, Llc Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors
WO2024038089A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Also Published As

Publication number Publication date
JP4086663B2 (ja) 2008-05-14
TWI267509B (en) 2006-12-01
EP1373224A1 (en) 2004-01-02
US20070049558A1 (en) 2007-03-01
SI1373224T1 (sl) 2007-10-31
IL157659A0 (en) 2004-03-28
CY1106829T1 (el) 2012-05-23
GT200200053A (es) 2003-02-12
IL157659A (en) 2008-08-07
HK1061854A1 (en) 2004-10-08
TNSN03076A1 (en) 2005-12-23
CZ20032451A3 (cs) 2004-09-15
CN1498212A (zh) 2004-05-19
BG108181A (en) 2004-09-30
MA27001A1 (fr) 2004-12-20
WO2002074754A1 (en) 2002-09-26
HUP0303637A2 (hu) 2004-03-01
YU74003A (sh) 2006-05-25
EE200300459A (et) 2004-02-16
OA12454A (en) 2004-09-30
SK11562003A3 (sk) 2005-01-03
EP1373224B1 (en) 2007-07-18
CU23218A3 (es) 2007-07-20
PA8541601A1 (es) 2003-05-14
RS50429B (sr) 2009-12-31
WO2002076953A1 (en) 2002-10-03
KR100617435B1 (ko) 2006-08-31
US7214676B2 (en) 2007-05-08
IS6934A (is) 2003-08-29
SV2003000925A (es) 2003-05-20
PL367058A1 (en) 2005-02-21
UA74243C2 (ru) 2005-11-15
MY142045A (en) 2010-08-30
NZ527847A (en) 2005-06-24
IS2529B (is) 2009-07-15
AR033617A1 (es) 2003-12-26
AP2003002857A0 (en) 2003-09-30
CA2441313A1 (en) 2002-09-26
BR0208192A (pt) 2004-03-02
EA200300906A1 (ru) 2004-02-26
PT1373224E (pt) 2007-09-25
ZA200306601B (en) 2004-08-25
AU2002304800B2 (en) 2007-08-30
PE20021010A1 (es) 2003-02-01
EP1801106A3 (en) 2007-07-04
CN100447136C (zh) 2008-12-31
HRP20030740A2 (en) 2005-06-30
US20040214843A1 (en) 2004-10-28
DK1373224T3 (da) 2007-10-15
NO20034187L (no) 2003-10-15
KR20030086315A (ko) 2003-11-07
DE60221233T2 (de) 2008-04-03
NO326086B1 (no) 2008-09-15
ECSP034750A (es) 2003-10-28
CA2441313C (en) 2009-03-31
NO20034187D0 (no) 2003-09-19
AP1699A (en) 2006-12-26
GEP20053631B (en) 2005-10-10
EA006815B1 (ru) 2006-04-28
ATE367381T1 (de) 2007-08-15
HUP0303637A3 (en) 2004-07-28
JP2004529123A (ja) 2004-09-24
DE60221233D1 (de) 2007-08-30
ES2288552T3 (es) 2008-01-16
EP1801106A2 (en) 2007-06-27
MXPA03008485A (es) 2003-12-08

Similar Documents

Publication Publication Date Title
US20020198198A1 (en) Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
AU2002304800A1 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US7429598B2 (en) Spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
CA2701150C (fr) Derives de quinazolinedione, leur preparation et leurs applications therapeutiques
EP0464604B1 (en) 1-Indolylalkyl-4-(alkoxy-pyrimidinyl)piperazines
CA2589328A1 (en) Multicyclic bis-amide mmp inhibitors
CA2652852A1 (fr) Derives d'urees de piperidine ou pyrrolidine, leur preparation et leur application en therapeutique
RU2190612C2 (ru) Новые производные индол-2,3-дион-3-оксима
JPH0873439A (ja) １−ベンジル−１，３−ジヒドロ−２ｈ−ベンズイミダゾール−２−オン誘導体、これらの調製およびこれらを含有する薬学的組成物
RU2284325C2 (ru) Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе
EP0415634A2 (en) Benzazabicyclic carbamates as cholinesterase inhibitors
SI9300542A (en) Benzofuran derivatives for medical use
AU2007240176A1 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
JPH0525140A (ja) ベンズイミダゾール誘導体
TW200536834A (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors

Legal Events

Date Code Title Description
AS Assignment

Owner name: WARNER-LAMBERT COMPANY LLC, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BERNARDELLI, PATRICK;DUCROT, PIERRE;LORTHIOIS, EDWIGE;AND OTHERS;REEL/FRAME:013844/0501

Effective date: 20030227

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION